POST-USTEKINUMAB INDUCTION IL-12, IL-23, AND USTEKINUMAB LEVELS ARE ASSOCIATED WITH CLINICAL RESPONSE IN A MULTICENTRE PROSPECTIVE COHORT STUDY OF CROHN'S DISEASE PATIENTS: RESULTS FROM THE AURORA STUDY

被引：0
|
作者：
An, Yoon-Kyo
Lindsay, Niamh
Allan, Natalie
Khoo, Emi
Fernandes, Richard
Amiss, Anna
Hai Pham
Wong, Kam Fai
Ooi, Soong-Yuan
Thin, Lena
Lightowler, Daniel
Connor, Susan J.
Williams, Astrid-Jane
De Cruz, Peter
Suen, Christopher Li Wai
Kariyawasam, Viraj C.
Mitrev, Nikola
Ghaly, Simon
Andrews, Jane M.
Christensen, Britt
Sparrow, Miles
White, Lauren S.
Bryant, Robert V.
Ding, Nik S.
Leong, Rupert
Van Langenberg, Daniel R.
Seltenreich, Hansjoerg
Subramaniam, Kavitha
Radford-Smith, Graham L.
Begun, Jakob
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Tu1749
引用
收藏
页码：S1108 / S1108
页数：1
相关论文
共 50 条
  • [31] Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab - A prospective, multicenter cohort from Hungary
    Gonczi, Lorant
    Szanto, Kata
    Farkas, Klaudia
    Molnar, Tamas
    Szamosi, Tamas
    Schafer, Eszter
    Golovics, Petra A.
    Barkai, Laszlo
    Lontai, Livia
    Lovasz, Barbara
    Juhasz, Mark
    Patai, Arpad
    Sarang, Krisztina
    Vincze, Aron
    Sarlos, Patricia
    Farkas, Alexandra
    Dubravcsik, Zsolt
    Toth, Tamas G.
    Miheller, Pal
    Ilias, Akos
    Lakatos, Peter L.
    DIGESTIVE AND LIVER DISEASE, 2022, 54 (02) : 207 - 213
  • [32] LONG-TERM CLINICAL EFFECTIVENESS OF USTEKINUMAB IN JAPANESE PATIENTS WITH CROHN'S DISEASE: A RETROSPECTIVE COHORT STUDY
    Ito, Takahiro
    Maemoto, Atsuo
    Katsurada, Takehiko
    Motoya, Satoshi
    Ueno, Nobuhiro
    Fujiya, Mikihiro
    Ashida, Toshifumi
    Hirayama, Daisuke
    Nakase, Hiroshi
    GASTROENTEROLOGY, 2022, 162 (07) : S1099 - S1099
  • [33] Pharmacokinetics, Exposure-Response Relationships, and Immunogenicity in Crohn's Disease Patients With Ustekinumab Secondary Loss of Response Following Ustekinumab IV Re-Induction: Week 16 Results From the POWER Study
    Feagan, Brian G.
    Lee, Scott D.
    van der Woude, C. Janneke
    Marin-Jimenez, Ignacio
    Wolf, Douglas C.
    Schnoy, Elisabeth
    Salzberg, Bruce
    Busse, Christopher
    Nazar, Maciej
    Langholff, Wayne
    Gasink, Christopher
    Baker, Thomas
    Godwin, Bridget
    Adedokun, Omoniyi
    Schreiber, Stefan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S622 - S622
  • [34] Ustekinumab for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study
    Straatmijer, T.
    Biemans, V. B. C.
    Hoentjen, F.
    de Boer, N. K. H.
    Bodelier, A. G.
    Dijkstra, G.
    van Dop, W.
    Haans, J. J. L.
    Jansen, J. M.
    Maljaars, P. W. J.
    van der Marel, S.
    Oldenburg, B.
    Ponsioen, C. Y.
    Visschedijk, M. C.
    de Vries, A. C.
    West, R.
    van der Woudeu, C. J.
    Pierik, M.
    Duijvestein, M.
    van der Meulen-de Jong, A. E.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S319 - S319
  • [35] PREOPERATIVE USTEKINUMAB TREATMENT IS NOT ASSOCIATED WITH INCREASED POSTOPERATIVE COMPLICATIONS IN CROHN'S DISEASE: A CANADIAN MULTICENTRE CASE-CONTROL COHORT STUDY
    Shim, Hang Hock
    Ma, Christopher
    Al-Farhan, Heba
    Al-Darmaki, Ahmed
    Pang, Jack X.
    Seow, Cynthia H.
    Fedorak, Richard N.
    Devlin, Shane M.
    Dieleman, Levinus A.
    Kaplan, Gilaad
    Novak, Kerri L.
    Kroeker, Karen I.
    Halloran, Brendan P.
    Panaccione, Remo
    GASTROENTEROLOGY, 2017, 152 (05) : S577 - S577
  • [36] Association between Ustekinumab Trough Levels, Serum IL-22 and Oncostatin M Levels with Clinical and Biochemical Outcomes in Patients With Crohn's Disease
    Bertin, L.
    Gubbiotti, A.
    Buda, A.
    Zingone, F.
    Savarino, E. V.
    Barberio, B.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 943 - 943
  • [37] Real World Evidence on the effectiveness of ustekinumab in Crohn's Disease: Induction phase results from the prospective, observational RUN-CD Study
    Bokemeyer, B.
    Plachta-Danielzik, S.
    Di Giuseppe, R.
    Mohl, W.
    Teich, N.
    Hoffstadt, M.
    Schweitzer, A.
    von der Ohe, M.
    Gauss, A.
    Atreya, R.
    Krause, T.
    Blumenstein, I.
    Hoechstoedter, J.
    Hartmann, P.
    Schreiber, S.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S083 - S084
  • [38] Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn's Disease
    Bertin, Luisa
    Barberio, Brigida
    Gubbiotti, Alessandro
    Bertani, Lorenzo
    Costa, Francesco
    Ceccarelli, Linda
    Visaggi, Pierfrancesco
    Bodini, Giorgia
    Pasta, Andrea
    Sablich, Renato
    Urbano, Maria Teresa
    Ferronato, Antonio
    Buda, Andrea
    De Bona, Manuela
    Del Corso, Giulio
    Massano, Alessandro
    Angriman, Imerio
    Scarpa, Marco
    Zingone, Fabiana
    Savarino, Edoardo Vincenzo
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (06)
  • [39] USTEKINUMAB DRUG CLEARANCE IS BETTER ASSOCIATED WITH CROHN'S DISEASE REMISSION THAN SERUM TROUGH CONCENTRATIONS IN PROSPECTIVE COHORT STUDY
    Yarur, Andres
    Dervieux, Thierry
    Ungaro, Ryan C.
    Bruss, Alexandra
    Berens, Brandon
    Nunez, Lizbeth
    Vermeire, Severine
    Wang, Zhigang
    Dreesen, Erwin
    Dubinsky, Marla C.
    GASTROENTEROLOGY, 2024, 166 (05) : S829 - S830
  • [40] Ustekinumab tissue and serum levels in patients with Crohn's disease are closely correlated though not consistently associated with objective response after induction
    Proietti, E.
    Bayoumy, A.
    Pauwels, R.
    van der Woude, J.
    Doukas, M.
    Oudijk, L.
    Peppelenbosch, M.
    Grohmann, U.
    Crombag, R.
    de Vries, A.
    Fuhler, G.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I500 - I501
12345